Drug intelligence / Profile preview

HY0301

Development stage: Unknown
Lead developer: Shanghai HyaMab Biotechnology
Modality: Cell Therapies

Overview

HY0301 is a cell therapy drug candidate developed by Shanghai HyaMab Biotechnology. It is currently in the discovery phase of development and is being investigated for use in neoplasms, particularly glioma and hematologic neoplasms. The precise mechanism of action, molecular target(s), and detailed modality characteristics have not been disclosed publicly as of the latest available update. Its therapeutic focus includes both solid tumors (glioma) and blood cancers (hematologic neoplasms)[1].

Beyond the preview

Go deeper on HY0301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HY0301.

Explore the full profile